Di Bartolomeo Salvatore, Alunno Alessia, Carubbi Francesco
Department of Medicine, ASL 1 Avezzano-Sulmona-L'Aquila, 67039 Sulmona, Italy.
Rheumatology Unit, Department of Medicine, University of Perugia, 06123 Perugia, Italy.
Pharmaceuticals (Basel). 2021 Mar 18;14(3):276. doi: 10.3390/ph14030276.
Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease characterized by a wide spectrum of clinical manifestations. The respiratory system can be involved in up to 50-70% of patients and be the presenting manifestation of the disease in 4-5% of cases. Every part of the respiratory part can be involved, and the severity can vary from mild self-limiting to life threatening forms. Respiratory involvement can be primary (caused by SLE itself) or secondary (e.g., infections or drug toxicity), acute or chronic. The course, treatment and prognosis vary greatly depending on the specific pattern of the disease. This review article aims at providing an overview of respiratory manifestations in SLE along with an update about therapeutic approaches including novel biologic therapies.
系统性红斑狼疮（SLE）是一种慢性全身性自身免疫性疾病，其临床表现多种多样。呼吸系统受累在高达50%-70%的患者中出现，在4%-5%的病例中是该疾病的首发表现。呼吸系统的各个部位均可受累，严重程度可从轻度自限性到危及生命的形式不等。呼吸系统受累可为原发性（由SLE本身引起）或继发性（如感染或药物毒性），急性或慢性。其病程、治疗和预后因疾病的具体类型而有很大差异。这篇综述文章旨在概述SLE的呼吸系统表现，并介绍包括新型生物疗法在内的治疗方法的最新进展。
